Market Closed -
Nasdaq
04:00:00 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
4.38
USD
|
+4.04%
|
|
+7.88%
|
-12.57%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
273.2
|
154.7
|
49.41
|
52.9
|
124.1
|
180.4
|
-
|
-
|
Enterprise Value (EV)
1 |
273.2
|
154.7
|
49.41
|
52.9
|
124.1
|
114.1
|
187.8
|
180.4
|
P/E ratio
|
-2.17
x
|
-1.73
x
|
-0.39
x
|
-0.56
x
|
-1.98
x
|
-2.39
x
|
-2.85
x
|
-14.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
15.5
x
|
16.5
x
|
37.4
x
|
35.5
x
|
-
|
10.9
x
|
2.01
x
|
EV / Revenue
|
-
|
15.5
x
|
16.5
x
|
37.4
x
|
35.5
x
|
-
|
11.4
x
|
2.01
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-3.95
x
|
-4.25
x
|
-
|
-
|
-
|
-1.46
x
|
-3.14
x
|
-25.4
x
|
FCF Yield
|
-25.3%
|
-23.5%
|
-
|
-
|
-
|
-68.7%
|
-31.9%
|
-3.94%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
3,341
|
3,941
|
5,865
|
17,176
|
24,773
|
41,186
|
-
|
-
|
Reference price
2 |
81.75
|
39.25
|
8.425
|
3.080
|
5.010
|
4.380
|
4.380
|
4.380
|
Announcement Date
|
3/16/20
|
3/24/21
|
3/31/22
|
3/29/23
|
3/18/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
10
|
3
|
1.414
|
3.5
|
-
|
16.54
|
89.65
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-77.09
|
-81.42
|
-89.84
|
-50.92
|
-47.14
|
-59.56
|
-56.74
|
6.279
|
Operating Margin
|
-
|
-814.2%
|
-2,994.53%
|
-3,600.78%
|
-1,346.71%
|
-
|
-342.97%
|
7%
|
Earnings before Tax (EBT)
1 |
-76.28
|
-84.23
|
-84.94
|
-39.7
|
-54.19
|
-70.28
|
-65.12
|
-21.5
|
Net income
1 |
-76.28
|
-84.23
|
-84.94
|
-43.48
|
-54.19
|
-70.28
|
-65.12
|
-25.25
|
Net margin
|
-
|
-842.34%
|
-2,831.2%
|
-3,074.82%
|
-1,548.23%
|
-
|
-393.66%
|
-28.17%
|
EPS
2 |
-37.75
|
-22.75
|
-21.50
|
-5.530
|
-2.530
|
-1.830
|
-1.538
|
-0.3033
|
Free Cash Flow
1 |
-69.13
|
-36.36
|
-
|
-
|
-
|
-78.4
|
-59.85
|
-7.1
|
FCF margin
|
-
|
-363.55%
|
-
|
-
|
-
|
-
|
-361.78%
|
-7.92%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/16/20
|
3/24/21
|
3/31/22
|
3/29/23
|
3/18/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
3
|
0.346
|
1
|
-
|
0.068
|
-
|
3.5
|
-
|
-
|
0.125
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-14.87
|
-46.65
|
-20.59
|
-8.008
|
-9.38
|
-12.94
|
-12.04
|
-11.62
|
-11.33
|
-13.21
|
-14.33
|
-14.34
|
-15.18
|
-15.73
|
-
|
Operating Margin
|
-
|
-1,555.07%
|
-5,951.16%
|
-800.8%
|
-
|
-19,023.53%
|
-
|
-331.97%
|
-
|
-
|
-11,040%
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-7.044
|
-46.68
|
-20.79
|
-8.295
|
-9.484
|
-1.126
|
-9.107
|
-16.65
|
-11.84
|
-16.59
|
-31.58
|
-14.07
|
-15.47
|
-16.8
|
-
|
Net income
1 |
-7.044
|
-46.68
|
-20.79
|
-12.08
|
-9.484
|
-1.126
|
-9.107
|
-16.65
|
-11.84
|
-16.59
|
-31.58
|
-14.07
|
-15.47
|
-16.8
|
-
|
Net margin
|
-
|
-1,556.1%
|
-6,008.96%
|
-1,207.7%
|
-
|
-1,655.88%
|
-
|
-475.83%
|
-
|
-
|
-11,200%
|
-
|
-
|
-
|
-
|
EPS
2 |
-1.750
|
-11.25
|
-3.500
|
-2.080
|
-1.480
|
-
|
-0.5400
|
-0.9200
|
-0.4800
|
-0.6400
|
-1.160
|
-0.3300
|
-0.3533
|
-0.3800
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/15/21
|
3/31/22
|
5/13/22
|
8/11/22
|
11/14/22
|
3/29/23
|
5/11/23
|
8/8/23
|
11/13/23
|
3/18/24
|
5/15/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
7.4
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
66.3
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-69.1
|
-36.4
|
-
|
-
|
-
|
-78.4
|
-59.9
|
-7.1
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
6.31
|
1.34
|
-
|
-
|
-
|
8.6
|
3
|
3.5
|
Capex / Sales
|
-
|
13.36%
|
-
|
-
|
-
|
-
|
18.13%
|
3.9%
|
Announcement Date
|
3/16/20
|
3/24/21
|
3/31/22
|
3/29/23
|
3/18/24
|
-
|
-
|
-
|
Last Close Price
4.38
USD Average target price
19.7
USD Spread / Average Target +349.77% Consensus |
1st Jan change
|
Capi.
|
---|
| -12.57% | 180M | | +43.36% | 54.64B | | -5.31% | 39.92B | | +37.52% | 38.82B | | +14.75% | 26.86B | | -12.56% | 26.22B | | -22.45% | 18.78B | | +0.04% | 12.16B | | +25.12% | 12.21B | | +26.04% | 11.94B |
Other Biotechnology & Medical Research
|